抗CD33抗体在治疗急性髓系白血病中的应用
摘要
CD33抗原是靶向治疗急性髓系白血病的一个合适的靶点,抗CD33单克隆抗体经过基因工程改造后,可通过抗体依赖性细胞毒作用杀伤靶细胞,并且可将靶向性单抗与细胞毒药物或放射性同位素偶联杀伤靶细胞,发挥治疗作用。抗CD33单抗GO(gemtuzumab ozogamicin)已用于临床治疗。本文就抗 CD33抗体在治疗急性髓系白血病中的应用作一综述。
出处
《国外医学（输血及血液学分册）》
CAS
2005年第4期361-363,共3页
Foreign Medical Sciences(Section of Blood Transfusion and Heanatology)
参考文献21
-
1Sievers EL. Targeted therapy of acute myeloid leukemia with monoclonal antibody and immunoconjugates. Cancer Chemother Pharmacol, 2000,46 (Suppl): S18-22.
-
2Ruffner KL, Matthews DC. Current use of monoclonal antibody in the treatment of acute leukemia. Semin Oncol, 2000,27 (5):531-539.
-
3Scheinberg DA, Tanimoto M, McKenzie S, et al. Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. Leukemia, 1989,3(6): 440-445.
-
4Feldman E, Kalaycio M, Schulman P, et al. Humanized monoclonal anti-CD33 antibody HuM195 in the treatment of relapsed/refractory acute myelogenous leukemia ( AML ):preliminary report of a phase Ⅱ study. Proc Annu Meet Am Soc Clin Oncol, 1999, 18:4a.
-
5Feldman E, Kalaycio M, Weiner G, et al. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia, 2003,17(2): 314-318.
-
6Jurcic JG, DeBlasio T, Dumont L, et al. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res 2000,6(2) : 372-380.
-
7Burke JM, Jurcic JG. Antibody therapy in acute myeloid leukemia: current status and future directions. Clin Lymphoma,2002,2 (Suppl 1): S12-18.
-
8Bross PF, Beitz J, Chen G, et al. Approval summary:Gemtuzumab Ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res, 2001,7(6): 1490-1496.
-
9Sievers EL. Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg). Blood Cells Mol Dis, 2003,31(1): 7-10.
-
10Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood, 1999,93(11): 3678-3684.
-
1左玉丰,廖晓龙.抗CD33抗体在急性髓系白血病治疗中的作用[J].实用老年医学,2004,18(2):96-97.
-
2马军,陆泽生.人源化CD33单克隆抗体联合化疗与单用化疗在初次复发或难治性急性髓性白血病治疗中比较的Ⅲ期多中心随机研究的评价[J].循证医学,2007,7(4):213-215.
-
3马军.老年急性早幼粒细胞白血病的治疗[J].实用老年医学,2004,18(2):63-64. 被引量：4
-
4王谦,仇惠英,吴德沛,孙爱宁,金正明,苗瞄,唐晓文,傅铮铮,韩悦,何广胜.抗CD33单抗联合化疗药物治疗复发或难治性急性髓系白血病的疗效观察[J].苏州大学学报（医学版）,2011,31(2):317-320. 被引量：6
-
5程澍,李军民,沈志祥.抗CD33单克隆抗体在急性髓细胞性白血病中的应用[J].中国处方药,2005,4(8):44-47. 被引量：2
-
6梁波,李维佳,张学美.CD33单克隆抗体GO在白血病治疗中的应用[J].中国医疗前沿,2008,3(10):34-36.
-
7邢平平,孙考祥,冯东晓.抗体介导的靶向给药系统研究进展[J].生物技术通讯,2017,28(2):196-201. 被引量：1
-
8贾新颜,许小平.Mylotarg在急性髓细胞白血病治疗中的应用[J].国外医学（输血及血液学分册）,2005,28(2):140-143. 被引量：1
-
9朱久进,谢家庆,王远亮,秦素华.高分子偶联靶向药物的研究进展[J].生物医学工程研究,2004,23(4):249-252. 被引量：2
-
10陈泽,王建祥.单克隆抗体靶向治疗急性髓系白血病[J].国外医学（输血及血液学分册）,2004,27(4):332-335. 被引量：1
